HIV therapeutic vaccine enhances non-exhausted CD4(+) T cells in a randomised phase 2 trial

VAC-3S is a therapeutic vaccine comprising a highly conserved HIV-gp41 motif coupled with the CRM197 carrier protein. High levels of anti-3S antibodies (Abs) have been associated with improved protection of CD4(+) T-cell survival. A previous phase 1 study demonstrated the safety of VAC-3S. This mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Vieillard, Vincent, Combadière, Béhazine, Tubiana, Roland, Launay, Odile, Pialoux, Gilles, Cotte, Laurent, Girard, Pierre-Marie, Simon, Anne, Dudoit, Yasmine, Reynes, Jacques, Rockstroh, Jürgen, Garcia, Felipe, Gatell, Jose, Devidas, Alain, Yazdanpanah, Yazdan, Weiss, Laurence, Fätkenheuer, Gerd, Autran, Brigitte, Joyeux, Delphine, Gharakhanian, Shahin, Debré, Patrice, Katlama, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546693/
https://www.ncbi.nlm.nih.gov/pubmed/31231551
http://dx.doi.org/10.1038/s41541-019-0117-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546693/
https://www.ncbi.nlm.nih.gov/pubmed/31231551
http://dx.doi.org/10.1038/s41541-019-0117-5

Ejemplares similares